PDS Biotechnology to Present at the World Vaccine & Immunotherapy Congress West Coast 2019
PDS Biotechnology Corporation (PDSB)
Last pds biotechnology corporation earnings: 11/7 06:00 am
Check Earnings Report
Company Research
Source: GlobeNewswire
PRINCETON, N.J., Nov. 25, 2019 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immuno-oncology company developing multiple therapies based on the Company’s proprietary Versamune® T-cell activating technology, today announced that Lauren V. Wood, M.D., Chief Medical Officer of PDS Biotechnology, has been selected to deliver an oral presentation on the Company’s novel T-cell activating immunotherapy platform, Versamune®, at the World Vaccine & Immunotherapy Congress West Coast 2019, taking place on December 2-5, 2019 in San Francisco, CA. Details for the presentation are below: Presentation Title: Versamune®: A Novel T-cell Activating Immunotherapy PlatformTopic: Engaging T-Cells, Cancer Antibodies, and CombinationsPresenter: Dr. Lauren V. Wood, Chief Medical Officer, PDS BiotechnologyDate: Wednesday, December 4, 2019Time: 3:00pm PST The Versamune® platform is PDS Biotech’s proprietary, synthetic lipid-based T-cell activating platform, which works
Show less
Read more
Impact Snapshot
Event Time:
PDSB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PDSB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PDSB alerts
High impacting PDS Biotechnology Corporation news events
Weekly update
A roundup of the hottest topics
PDSB
News
- Down -35.74% in 4 Weeks, Here's Why PDS Biotechnology (PDSB) Looks Ripe for a Turnaround [Yahoo! Finance]Yahoo! Finance
- PDS Biotechnology Co. (NASDAQ: PDSB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.MarketBeat
- PDS Biotechnology Corp (PDSB) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges ... [Yahoo! Finance]Yahoo! Finance
- PDS Biotech Provides Clinical Programs Update and Reports Third Quarter 2024 Financial Results [Yahoo! Finance]Yahoo! Finance
- PDS Biotech Provides Clinical Programs Update and Reports Third Quarter 2024 Financial ResultsGlobeNewswire
PDSB
Earnings
- 11/14/24 - In-Line
PDSB
Sec Filings
- 11/14/24 - Form 10-Q
- 11/14/24 - Form 8-K
- 10/2/24 - Form 8-K
- PDSB's page on the SEC website